Acasti Pharma Q1 FY2025 net loss $2.6M; STRIVE-ON trial enrollment exceeds 50%

Grace Therapeutics, Inc.

2024-Q1 EPS reported -$0.24

Net loss of $2.6M ($0.24 loss per share) vs $4.0M ($0.54) in prior-year quarter.
Cash and equivalents $19.4M as of June 30, 2024; projected runway into Q2 2026.
Pivotal Phase 3 STRIVE-ON safety trial surpassed 50% enrollment; completion expected late 2024 to early 2025.
NDA submission to FDA for GTX-104 anticipated in first half of calendar 2025.
R&D expenses rose to $2.7M from $1.1M, driven by GTX-104 clinical activities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.